Antitussive effects of NaV 1.7 blockade in Guinea pigs

Li Yu, Kojun Tsuji, Izumi Ujihara, Qi Liu, Nikoleta Pavelkova, Takanori Tsujimura, Makoto Inoue, Sonya Meeker, Eric Nisenbaum, Jeff S. McDermott, Jeff Krajewski, Bradley J. Undem, Marian Kollarik, Brendan J. Canning

Research output: Contribution to journalArticlepeer-review

Abstract

Our previous studies implicated the voltage-gated sodium channel subtype NaV 1.7 in the transmission of action potentials by the vagal afferent nerves regulating cough and thus identified this channel as a rational therapeutic target for antitussive therapy. But it is presently unclear whether a systemically administered small molecule inhibitor of NaV 1.7 conductance can achieve therapeutic benefit in the absence of side effects on cardiovascular function, gastrointestinal motility or respiration. To this end, we have evaluated the antitussive effects of the NaV 1.7 selective blocker Compound 801 administered systemically in awake guinea pigs or administered topically in anesthetized guinea pigs. We also evaluated the antitussive effects of ambroxol, a low affinity NaV blocker modestly selective for tetrodotoxin resistant NaV subtypes. Both Compound 801 and ambroxol dose-dependently inhibited action potential conduction in guinea pig vagus nerves (assessed by compound potential), with ambroxol nearly 100-fold less potent than the NaV 1.7 selective Compound 801 in this and other NaV 1.7-dependent guinea pig and human tissue-based assays. Both drugs also inhibited citric acid evoked coughing in awake or anesthetized guinea pigs, with potencies supportive of an NaV 1.7-dependent mechanism. Notably, however, the antitussive effects of systemically administered Compound 801 were accompanied by hypotension and respiratory depression. Given the antitussive effects of topically administered Compound 801, we speculate that the likely insurmountable side effects on blood pressure and respiratory drive associated with systemic dosing make topical formulations a viable and perhaps unavoidable therapeutic strategy for targeting NaV 1.7 in cough.

Original languageEnglish (US)
Article number174192
JournalEuropean Journal of Pharmacology
Volume907
DOIs
StatePublished - Sep 15 2021

Keywords

  • Ambroxol
  • Cardiovascular
  • Pain
  • Respiratory
  • Sodium channel
  • Vagal

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Antitussive effects of Na<sub>V</sub> 1.7 blockade in Guinea pigs'. Together they form a unique fingerprint.

Cite this